TABLE 6.
Recognition of DCs Transfected with NY-ESO-1 IVT RNA in the Presence or Absence of Maturation Cytokines by HLA-A*0201 (A2) and HLA-DPβ1*0401 (DP4) Restricted, NY-ESO-1-reactive T-cell Populations*
| Target Cells | HLA Expression | Preloaded Peptide† | Genetic Modification | Maturation Cytokines‡ | TH1F2L (A2) Exp. 1 | SG6 (DP4) Exp. 1 | J-H1 (A2) Exp. 2 | M8 (A2) Exp. 2 | SG6 (DP4) Exp. 2 |
|---|---|---|---|---|---|---|---|---|---|
| Donor 12 DC | A2+DP4+ | — | ESO RNA | None | 377§ | 14 | — | — | — |
| Donor 12 DC | A2+DP4+ | — | GFP RNA | None | 52 | 0 | — | — | — |
| Donor 13 DC | A2+DP4+ | — | ESO RNA | None | 279 | 13 | — | — | — |
| Donor 13 DC | A2+DP4+ | — | GFP RNA | None | 86 | 5 | — | — | — |
| Donor 14 DC | A2+DP4+ | — | ESO RNA | None | 897 | 13 | — | — | — |
| Donor 14 DC | A2+DP4+ | — | GFP RNA | None | 215 | 5 | — | — | — |
| Donor 15 DC | A2+DP4+ | — | ESO RNA | None | — | — | 14 | 28 | 17 |
| Donor 15 DC | A2+DP4+ | — | GFP RNA | None | — | — | 14 | 15 | 18 |
| Donor 15 DC | A2+DP4+ | — | ESO RNA | CD40L+LPS | — | — | 166 | 267 | 605 |
| Donor 15 DC | A2+DP4+ | — | GFP RNA | CD40L+LPS | — | — | 15 | 16 | 17 |
| Donor 16 DC | A2+DP4+ | — | ESO RNA | None | — | — | 16 | 63 | 19 |
| Donor 16 DC | A2+DP4+ | — | GFP RNA | None | — | — | 18 | 33 | 17 |
| Donor 16 DC | A2+DP4+ | — | ESO RNA | CD40L+LPS | — | — | 32 | 81 | 211 |
| Donor 16 DC | A2+DP4+ | — | GFP RNA | CD40L+LPS | — | — | 24 | 56 | 74 |
| T2 cells | A2+ | HBVc:18–26(23Y) | 388 | — | 17 | 14 | — | ||
| T2 cells | A2+ | ESO:157–165 | > 2000 | — | 1294 | 1264 | — | ||
| EBV-B | DP4+ | HA:306–324 | — | — | — | — | — | — | 62 |
| EBV-B | DP4+ | ESO:161–180 | — | — | — | — | — | — | 1366 |
| 624mel | A2+DP4− | — | — | — | 1766 | 21 | — | — | — |
| 888mel | A2−DP4− | — | — | — | 39 | 9 | — | — | — |
IFNγ secretion (pg/mL) in 20 h coculture supernatants of target cells expressing HLA-A*0201 and/or HLA-DPβ1*0401 with T lymphocytes.
EBV-B cells were preincubated with 50 μg/mL MHC class II-restricted peptides, and T2 cells were preincubated with 1 μg/mL MHC class I-restricted peptides.
DCs were matured with the indicated cytokines as described in the Materials and Methods section.
Underlined values indicate that IFNγ secretion in response to DCs genetically modified with NY-ESO-1 vectors, peptide-loaded T2 cells or EBV-B cells, or melanoma cell lines was ≥ 50 pg/mL and at least twice background with relevant control target cells.